Insights on structural characteristics and ligand binding mechanisms of CDK2

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 9314-9340

  Li, Yan ^a   Zhang, Jingxiao ^a,b   Gao, Weimin ^a   Zhang, Lilei ^b   Pan, Yanqiu ^a   Zhang, Shuwei ^a   Wang, Yonghua ^c  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b HUBEI UNIVERSITY FOR NATIONALITIES   (China)

^c NORTHWEST A F UNIVERSITY   (China)

Author keywords

Binding mechanism; CDK2 (cyclin dependent kinase 2); Variations

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BAY 1000394; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DINACICLIB; FLAVOPIRIDOL; MILCICLIB; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL] ISONIPECOTAMIDE; RGB 286638; ROSCOVITINE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; CDK2 PROTEIN, HUMAN; LIGAND; PROTEIN BINDING;

BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; HUMAN; HYDROGEN BOND; LIGAND BINDING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; REVIEW; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CATALYSIS; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETIC VARIATION; METABOLISM; MOLECULAR GENETICS; MOLECULAR MODEL; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

EUKARYOTA;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC SITE; AMINO ACID SEQUENCE; BINDING SITES; BINDING, COMPETITIVE; CATALYSIS; CLINICAL TRIALS AS TOPIC; CYCLIN A; CYCLIN B; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; GENETIC VARIATION; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84928384482     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16059314     Document Type: Review

References (101)

1. Gray, N.; Detivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859–875.
2. De Vivo, M.; Bottegoni, G.; Berteotti, A.; Recanatini, M.; Gervasio, F.L.; Cavalli, A. Cyclin-dependent kinases: Bridging their structure and function through computations. Future Med. Chem. 2011, 3, 1551–1559.
3. Bartkowiak, B.; Liu, P.; Phatnani, H.P.; Fuda, N.J.; Cooper, J.J.; Price, D.H.; Adelman, K.; Lis, J.T.; Greenleaf, A.L. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 2010, 24, 2303–2316.
4. Hardcastle, I.R.; Golding, B.T.; Griffin, R.J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325–348.
5. Lolli, G.; Johnson, L.N. CAK-Cyclin-dependent Activating Kinase: A key kinase in cell cycle control and a target for drugs? Cell Cycle 2005, 4, 572–577.
6. Jeffrey, P.D.; Russo, A.A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376, 313–320.
7. Larochelle, S.; Merrick, K.A.; Terret, M.E.; Wohlbold, L.; Barboza, N.M.; Zhang, C.; Shokat, K.M.; Jallepalli, P.V.; Fisher, R.P. Requirements for CDK7 in the assembly of CDK1/cyclin B and activation of CDK2 revealed by chemical genetics in human cells. Mol. Cell 2007, 25, 839–850.
8. Pillai, P.; Desai, S.; Patel, R.; Sajan, M.; Farese, R.; Ostrov, D.; Acevedo-Duncan, M. A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. Int. J. Biochem. Cell Biol. 2011, 43, 784–794.
9. Bica, L.; Meyerowitz, J.; Parker, S.J.; Caragounis, A.; Du, T.; Paterson, B.M.; Barnham, K.J.; Crouch, P.J.; White, A.R.; Donnelly, P.S. Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex. Biometals 2011, 24, 117–133.
10. Fisher, R.P.; Morgan, D.O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994, 78, 713–724.
11. Pavletich, N.P. Mechanisms of cyclin-dependent kinase regulation: Structures of cdks, their cyclin activators, and cip and INK4 inhibitors. J. Mol. Biol. 1999, 287, 821–828.
12. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res. 2000, 28, 235–242.
13. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24, 1770–1783.
14. Sherr, C.J. G1 phase progression: Cycling on cue. Cell 1994, 79, 551–555.
15. Pines, J. Cyclins: Wheels within wheels. Cell Growth Differ. 1991, 2, 305–310.
16. Toledo, L.M.; Lydon, N.B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6, 775–805.
17. Sherr, C.J. Cancer cell cycles. Science 1996, 274, 1672–1677.
18. Flores, O.; Wang, Z.; Knudsen, K.E.; Burnstein, K.L. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 2010, 151, 896–908.
19. Kawana, H.; Tamaru, J.-I.; Tanaka, T.; Hirai, A.; Saito, Y.; Kitagawa, M.; Mikata, A.; Harigaya, K.; Kuriyama, T. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am. J. Pathol. 1998, 153, 505–513.
20. Ali, S.; Heathcote, D.A.; Kroll, S.H.; Jogalekar, A.S.; Scheiper, B.; Patel, H.; Brackow, J.; Siwicka, A.; Fuchter, M.J.; Periyasamy, M. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009, 69, 6208–6215.
21. Johnson, N.; Bentley, J.; Wang, L.; Newell, D.; Robson, C.; Shapiro, G.; Curtin, N. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br. J. Cancer 2009, 102, 342–350.
22. Lees, J.A.; Weinberg, R.A. Tossing monkey wrenches into the clock: New ways of treating cancer. Proc. Natl. Acad. Sci. USA 1999, 96, 4221–4223.
23. Esposito, L.; Indovina, P.; Magnotti, F.; Conti, D.; Giordano, A. Anticancer therapeutic strategies based on CDK inhibitors. Curr. Pharm. Des. 2013, 19, 5327–5332.
24. Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J.R. CDK inhibitors in cancer therapy: What is next? Trends Pharmacol. Sci. 2008, 29, 16–21.
25. DePinto, W.; Chu, X.J.; Yin, X.; Smith, M.; Packman, K.; Goelzer, P.; Lovey, A.; Chen, Y.; Qian, H.; Hamid, R, et al. In vitro and in vivo activity of R547: A potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther. 2006, 5, 2644–2658.
26. MacCallum, D.E.; Melville, J.; Frame, S.; Watt, K.; Anderson, S.; Gianella-Borradori, A.; Lane, D.P.; Green, S.R. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 2005, 65, 5399–5407.
27. Rizzolio, F.; Tuccinardi, T.; Caligiuri, I.; Lucchetti, C.; Giordano, A. CDK inhibitors: From the bench to clinical trials. Curr. Drug Targets 2010, 11, 279–290.
28. Shirsath, N.P.; Manohar, S.M.; Joshi, K.S. P276–00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Mol. Cancer 2012, 11, 77, doi:10.1186/1476-4598-11-77.
29. Alessandri, A.L.; Duffin, R.; Leitch, A.E.; Lucas, C.D.; Sheldrake, T.A.; Dorward, D.A.; Hirani, N.; Pinho, V.; de Sousa, L.P.; Teixeira, M.M, et al. Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation. PLoS ONE 2011, 6, e25683.
30. Rigas, A.C.; Robson, C.N.; Curtin, N.J. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 2007, 26, 7611–7619.
31. Cicenas, J.; Valius, M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol. 2011, 137, 1409–1418.
32. Joshi, K.S.; Rathos, M.J.; Joshi, R.D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276–00. Mol. Cancer Ther. 2007, 6, 918–925.
33. Joshi, K.S.; Rathos, M.J.; Mahajan, P.; Wagh, V.; Shenoy, S.; Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H.H, et al. P276–00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol. Cancer Ther. 2007, 6, 926–934.
34. De Azevedo, W.F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S.H. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518–526.
35. Bagella, L.; Sun, A.; Tonini, T.; Abbadessa, G.; Cottone, G.; Paggi, M.G.; de Luca, A.; Claudio, P.P.; Giordano, A. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 2007, 26, 1829–1839.
36. Endicott, J.A.; Noble, M.E. Structural characterization of the cyclin-dependent protein kinase family. Biochem. Soc. Trans. 2013, 41, 1008–1016.
37. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86–8275. J. Natl. Cancer Inst. 1992, 84, 1736–1740.
38. De Azevedo, W., Jr; Mueller-Dieckmann, H.; Schulze-Gahmen, U.; Worland, P.; Sausville, E.; Kim, S. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA 1996, 93, 2735–2740.
39. Murthi, K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M.; Worland, P.; Mansuri, M.; Pal, K. Structure-activity relationship studies of flavopiridol analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037–1041.
40. McClue, S.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 2002, 102, 463–468.
41. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J.; Blow, J.; Inagaki, N.; Inagaki, M.; Delcros, J.; Moulinoux, J. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243, 527–536.
42. Caporali, S.; Alvino, E.; Starace, G.; Ciomei, M.; Brasca, M.; Levati, L.; Garbin, A.; Castiglia, D.; Covaciu, C.; Bonmassar, E. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol. Res. 2010, 61, 437–448.
43. Kawakami, K.; Futami, H.; Takahara, J.; Yamaguchi, K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun. 1996, 219, 778–783.
44. Li, T.; Christensen, S.; Frankel, P.; Margolin, K.; Agarwala, S.; Luu, T.; Mack, P.; Lara, P., Jr.; Gandara, D. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: A California Cancer Consortium trial. Investig. New Drugs 2012, 30, 741–748.
45. Senderowicz, A. The cell cycle as a target for cancer therapy: Basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002, 7, 12–19.
46. Chu, X.; DePinto, W.; Bartkovitz, D.; So, S.; Vu, B.; Packman, K.; Lukacs, C.; Ding, Q.; Jiang, N.; Wang, K. Discovery of (4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl)(2, 3-difluoro-6-methoxyphenyl) methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J. Med. Chem. 2006, 49, 6549–6560.
47. Mahadevan, D.; Plummer, R.; Squires, M.; Rensvold, D.; Kurtin, S.; Pretzinger, C.; Dragovich, T.; Adams, J.; Lock, V.; Smith, D. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann. Oncol. 2011, 22, 2137–2143.
48. Squires, M.S.; Cooke, L.; Lock, V.; Qi, W.; Lewis, E.J.; Thompson, N.T.; Lyons, J.F.; Mahadevan, D. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol. Cancer Ther. 2010, 9, 920–928.
49. Hallek, M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am. J. Hematol. 2013, 88, 803–816.
50. Parry, D.; Guzi, T.; Shanahan, F.; Davis, N.; Prabhavalkar, D.; Wiswell, D.; Seghezzi, W.; Paruch, K.; Dwyer, M.P.; Doll, R, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 2010, 9, 2344–2353.
51. Tong, W.; Chen, R.; Plunkett, W.; Siegel, D.; Sinha, R.; Harvey, R.; Badros, A.; Popplewell, L.; Coutre, S.; Fox, J. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J. Clin. Oncol. 2010, 28, 3015–3022.
52. Conroy, A.; Stockett, D.; Walker, D.; Arkin, M.; Hoch, U.; Fox, J.; Hawtin, R. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother. Pharmacol. 2009, 64, 723–732.
53. De Bruijn, P.; Moghaddam-Helmantel, I.; de Jonge, M.; Meyer, T.; Lam, M.; Verweij, J.; Wiemer, E.; Loos, W. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 2009, 50, 977–982.
54. Van der Biessen, D.A.; Burger, H.; de Bruijn, P.; Lamers, C.H.; Naus, N.; Loferer, H.; Wiemer, E.A.; Mathijssen, R.H.; de Jonge, M.J. Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors. Clin. Cancer Res. 2014, 20, 4776–4783.
55. Siemeister, G.; Lucking, U.; Wengner, A.; Lienau, P.; Schatz, C.; Mumberg, D.; Ziegelbauer, K. Pharmacologic profile of the oral novel pan-CDK inhibitor BAY 1000394 in chemosensitive and chemorefractory tumor models. Cancer Res. 2010, 70, 3883–3883.
56. Siemeister, G.; Lücking, U.; Wengner, A.; Lienau, P.; Steinke, W.; Schatz, C.; Mumberg, D.; Ziegelbauer, K. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono-and in combination treatment upon oral application. Mol. Cancer Ther. 2012, 11, 2265–2273.
57. Poulsen, A.; William, A.; Blanchard, S.; Nagaraj, H.; Williams, M.; Wang, H.; Lee, A.; Sun, E.; Teo, E.-L.; Tan, E. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). J. Mol. Model. 2013, 19, 119–130.
58. Desai, D.; Gu, Y.; Morgan, D.O. Activation of human cyclin-dependent kinases in vitro. Mol. Biol. Cell 1992, 3, 571–582.
59. Connell-Crowley, L.; Solomon, M.J.; Wei, N.; Harper, J.W. Phosphorylation independent activation of human cyclin-dependent kinase 2 by cyclin A in vitro. Mol. Biol. Cell 1993, 4, 79–92.
60. Gould, K.L.; Moreno, S.; Owen, D.J.; Sazer, S.; Nurse, P. Phosphorylation at Thr167 is required for Schizosaccharomyces pombe p34cdc2 function. EMBO J. 1991, 10, 3297–3309.
61. Gondeau, C.; Gerbal-Chaloin, S.; Bello, P.; Aldrian-Herrada, G.; Morris, M.C.; Divita, G. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J. Biol. Chem. 2005, 280, 13793–13800.
62. Krek, W.; Nigg, E.A. Cell cycle regulation of vertebrate p34cdc2 activity: Identification of Thr161 as an essential in vivo phosphorylation site. New Biol. 1992, 4, 323–329.
63. Gu, Y.; Rosenblatt, J.; Morgan, D.O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992, 11, 3995–4005.
64. Solomon, M.J. Activation of the various cyclin/cdc2 protein kinases. Curr. Opin. Cell Biol. 1993, 5, 180–186.
65. Ducommun, B.; Brambilla, P.; Felix, M.A.; Franza, B.R., Jr.; Karsenti, E.; Draetta, G. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J. 1991, 10, 3311–3319.
66. De Bondt, H.L.; Rosenblatt, J.; Jancarik, J.; Jones, H.D.; Morgan, D.O.; Kim, S.H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595–602.
67. Cox, S.; Radzio-Andzelm, E.; Taylor, S.S. Domain movements in protein kinases. Curr. Opin. Struct. Biol. 1994, 4, 893–901.
68. Brown, N.R.; Noble, M.E.; Endicott, J.A.; Johnson, L.N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 438–443.
69. Brown, N.R.; Noble, M.E.; Lawrie, A.M.; Morris, M.C.; Tunnah, P.; Divita, G.; Johnson, L.N.; Endicott, J.A. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 1999, 274, 8746–8756.
70. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases: Controlling activity through activation segment conformation. Mol. Cell 2004, 15, 661–675.
71. Holmes, J.K.; Solomon, M.J. The role of Thr160 phosphorylation of Cdk2 in substrate recognition. Eur. J. Biochem. 2001, 268, 4647–4653.
72. Davies, T.G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; Endicott, J.A.; Noble, M.E. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001, 9, 389–397.
73. Barrett, C.P.; Noble, M.E. Molecular motions of human cyclin-dependent kinase 2. J. Biol. Chem. 2005, 280, 13993–14005.
74. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417–425.
75. Sims, P.A.; Wong, C.F.; McCammon, J.A. A computational model of binding thermodynamics: The design of cyclin-dependent kinase 2 inhibitors. J. Med. Chem. 2003, 46, 3314–3325.
76. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: A network analysis. Bioinformatics 2010, 26, 198–204.
77. Tripathi, S.K.; Muttineni, R.; Singh, S.K. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. J. Theor. Biol. 2013, 334, 87–100.
78. Johnson, L.N.; de Moliner, E.; Brown, N.R.; Song, H.; Barford, D.; Endicott, J.A.; Noble, M.E. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol. Ther. 2002, 93, 113–124.
79. Xiang, J.; Yang, H.; Che, C.; Zou, H.; Wei, Y.; Quan, J.; Zhang, H.; Yang, Z.; Lin, S. Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays. PLoS ONE 2009, 4, e4361.
80. Li, Y.; Gao, W.; Li, F.; Wang, J.; Zhang, J.; Yang, Y.; Zhang, S.; Yang, L. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors. Mol. Biosyst. 2013, 9, 2266–2281.
81. Kim, K.S.; Kimball, S.D.; Misra, R.N.; Rawlins, D.B.; Hunt, J.T.; Xiao, H.Y.; Lu, S.; Qian, L.; Han, W.C.; Shan, W, et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem. 2002, 45, 3905–3927.
82. Sielecki, T.M.; Johnson, T.L.; Liu, J.; Muckelbauer, J.K.; Grafstrom, R.H.; Cox, S.; Boylan, J.; Burton, C.R.; Chen, H.; Smallwood, A, et al. Quinazolines as cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1157–1160.
83. Shafiq, M.I.; Steinbrecher, T.; Schmid, R. Fascaplysin as a specific inhibitor for CDK4: Insights from molecular modelling. PLoS ONE 2012, 7, e42612.
84. Mariaule, G.; Belmont, P. Cyclin-dependent kinase inhibitors as marketed anticancer drugs: Where Are We Now? A short survey. Molecules 2014, 19, 14366–14382.
85. Cadoo, K.A.; Gucalp, A.; Traina, T.A. Palbociclib: An evidence-based review of its potential in the treatment of breast cancer. Breast Cancer 2014, 6, 123–133.
86. Witkiewicz, A.K.; Knudsen, E.S. Retinoblastoma tumor suppressor pathway in breast cancer: Prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res. 2014, 16, 207. doi:10.1186/bcr3652.
87. McInnes, C.; Wang, S.; Anderson, S.; O’Boyle, J.; Jackson, W.; Kontopidis, G.; Meades, C.; Mezna, M.; Thomas, M.; Wood, G. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem. Biol. 2004, 11, 525–534.
88. Lu, H.; Schulze-Gahmen, U. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J. Med. Chem. 2006, 49, 3826–3831.
89. Chen, H.; van Duyne, R.; Zhang, N.; Kashanchi, F.; Zeng, C. A novel binding pocket of cyclin-dependent kinase 2. Proteins 2009, 74, 122–132.
90. Bogoyevitch, M.A.; Barr, R.K.; Ketterman, A.J. Peptide inhibitors of protein kinases-discovery, characterisation and use. Biochim. Biophys. Acta 2005, 1754, 79–99.
91. Honda, R.; Lowe, E.D.; Dubinina, E.; Skamnaki, V.; Cook, A.; Brown, N.R.; Johnson, L.N. The structure of cyclin E1/CDK2: Implications for CDK2 activation and CDK2-independent roles. EMBO J. 2005, 24, 452–463.
92. Brown, N.R.; Lowe, E.D.; Petri, E.; Skamnaki, V.; Antrobus, R.; Johnson, L.N. Cyclin B and cyclin A confer different substrate recognition properties on CDK2. Cell Cycle 2007, 6, 1350–1359.
93. Kaldis, P.; Sutton, A.; Solomon, M.J. The Cdk-activating kinase (CAK) from budding yeast. Cell 1996, 86, 553–564.
94. Betzi, S.; Alam, R.; Martin, M.; Lubbers, D.J.; Han, H.; Jakkaraj, S.R.; Georg, G.I.; Schonbrunn, E. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 2011, 6, 492–501.
95. Martin, M.P.; Alam, R.; Betzi, S.; Ingles, D.J.; Zhu, J.Y.; Schonbrunn, E. A novel approach to the discovery of small-molecule ligands of CDK2. Chembiochem 2012, 13, 2128–2136.
96. Rastelli, G.; Anighoro, A.; Chripkova, M.; Carrassa, L.; Broggini, M. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2. Cell Cycle 2014, 13, 2296–2305.
97. Pines, J. Four-dimensional control of the cell cycle. Nat. Cell Biol. 1999, 1, E73–E79.
98. Russo, A.A.; Jeffrey, P.D.; Pavletich, N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3, 696–700.
99. Knighton, D.R.; Zheng, J.H.; Ten Eyck, L.F.; Ashford, V.A.; Xuong, N.H.; Taylor, S.S.; Sowadski, J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991, 253, 407–414.
100. Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30, 630–641.
101. Cai, D.; Latham, V.M.; Zhang, X.; Shapiro, G.I. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 2006, 66, 9270–9280.